Abstract
Extramedullary plasmacytomas and prognostic implications in multiple myeloma
Highlights
Cutaneous plasmacytomas can occur primarily in the skin, without involvement of the bone marrow, or secondarily, from the dissemination of multiple myeloma or plasma cell leukemia [2]
We describe the case of a 68-year-old male, with an IgG lambda multiple myeloma under secondline therapy with bortezomib, thalidomide and dexamethasone after lack of response to first-line treatment, presenting to dermatology department due to the recent development of an erythematousviolaceous nodule of 1,2 cm of diameter on the left flank (Fig. 1), an occipital subcutaneous mass with 5 x 5 cm (Fig. 2) and 4 subcutaneous nodules on the forehead (Fig. 3), between 1,5 and 2 cm of diameter
Secondary cutaneous plasmacytomas occur by direct extension from underlying bone lesions or by hematogenic spread
Summary
Cutaneous plasmacytomas can occur primarily in the skin, without involvement of the bone marrow, or secondarily, from the dissemination of multiple myeloma or plasma cell leukemia [2]. We describe the case of a 68-year-old male, with an IgG lambda multiple myeloma under secondline therapy with bortezomib, thalidomide and dexamethasone after lack of response to first-line treatment, presenting to dermatology department due to the recent development of an erythematousviolaceous nodule of 1,2 cm of diameter on the left flank (Fig. 1), an occipital subcutaneous mass with 5 x 5 cm (Fig. 2) and 4 subcutaneous nodules on the forehead (Fig. 3), between 1,5 and 2 cm of diameter. Lesions were asymptomatic and had grown rapidly in size over weeks.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call